Providers

The investigators believe their decades-spanning analysis underscores the need to address access barriers to anti-obesity therapeutics.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.

The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years in patients with Duchenne muscular dystrophy (DMD).

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.

This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique histopathology and complications

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

Prophylactic cardiac treatment may prolong survival in Duchenne muscular dystrophy (DMD), but only one-quarter of individuals received such treatment, a recent study found.

Researchers suspect unmet treatment needs contribute to the shorter life expectancy for patients living with attention-deficit/hyperactivity disorder (ADHD).

The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).

Christopher Sayed, MD, discusses how hidradenitis suppurativa typically presents and looks forward, following the November approval of bimekizumab.

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.

Attorneys General from several districts have come together in a lawsuit seeking damages from Walgreens for allegedly knowingly filling opioid prescriptions that lacked a genuine medical purpose.

Peptidomics offered new diagnostic insights into the underlying processes of metabolic dyfunction-associated steatotic liver disease (MASLD).

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.

A new resource from the National Comprehensive Cancer Network (NCCN) provides evidence-based guidance on assessing and testing for inherited genetic mutations linked with increased cancer risk.

Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.

Patients with spinal muscular atrophy (SMA) type 2 showed improved motor ability when treated with intrathecal onasemnogene abeparvovec, an investigational gene therapy.

Across 5 research centers, investigators evaluated the impact of eculizumab on thymoma-associated myasthenia gravis, a severe disease subtype.

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

The results suggest that prolonging ambulation may not adversely impact cardiac function in adulthood for patients with Duchenne muscular dystrophy (DMD).

Respiratory patterns and submental surface electromyography may be a reliable indicator of dysphagia among patients with myasthenia gravis.

The bird flu, also known as avian influenza and H5N1, was implicated in the first human death from the infectious disease on January 6. But still, no human-to-human transmission has been reported.

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.